Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

Shots:

• The PRIME designation is based on two Phase I/II studies in R/R cHL conducted at Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center
• The studies showed the complete disappearance of tumors in ~60% of patients at the highest dose level with no serious toxicities, associated with several other CAR-T therapies. The results were published in Clinical Oncology
• The company plans to commence a multi-center pivotal study in the US during 2021. Additionally, P-I clinical study for patients with r/r CD30 positive NHL is open for enrollment in the US

Click here ­to­ read full press release/ article | Ref: PR Newswire | Image: PR Newswire